Dear HIV Community Writer,
ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine. This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that offer improvement over current options.
After much deliberation about how to proceed with lersivirine, it was determined that the compound would not provide an improvement over existing medicines in the NNRTI class, and that R&D resources for ViiV Healthcare should prioritize efforts to identify compounds that further HIV treatment.
We remain committed to exploring candidates that will advance HIV treatment and contribute to improving outcomes for people living with HIV.
Please don’t hesitate to reach out to me directly if you have any questions regarding this announcement.
Marc Meachem | Director, External Affairs